<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00224640</url>
  </required_header>
  <id_info>
    <org_study_id>P041201</org_study_id>
    <secondary_id>PCR 05001</secondary_id>
    <nct_id>NCT00224640</nct_id>
  </id_info>
  <brief_title>Iron-Chelating Therapy and Friedreich Ataxia</brief_title>
  <official_title>Effect of Iron-Chelating Therapy in Friedreich Ataxia. Study Phase I/II</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Assistance Publique - Hôpitaux de Paris</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Assistance Publique - Hôpitaux de Paris</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      Friedreich ataxia, an autosomal recessive condition, ascribed to frataxin gene expansion, has&#xD;
      been shown to result from an iron- induced injury to the mitochondrial respiratory chain.&#xD;
      Buffering free radicals with short-chain quinones (Idebenone) protects the patients against&#xD;
      cardiomyopathy but not CNS involvement. Removing CNS iron should limit the impact of the&#xD;
      neurological symptoms of the disease.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      The current clinical trial is a monocentric open phase1-2 trial in the context of rare&#xD;
      diseases framework, aimed to the goal of defining the tolerance/efficacy of the treatment.&#xD;
&#xD;
      Inclusion criteria: minimum age: 13 years Follow up in the Dept of Genetics, Hospital&#xD;
      Necker-Enfants Malades, Paris, France&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>March 2005</start_date>
  <completion_date type="Actual">March 2008</completion_date>
  <primary_completion_date type="Actual">March 2008</primary_completion_date>
  <phase>Phase 1/Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Non-Randomized</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>assessment of iron overload at TO and month2 by imagery</measure>
    <time_frame>at months :0, 1 ,2 ,4 ,6</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Clinical (monthly) and biological parameter follow- up ( blood count,</measure>
    <time_frame>weekly</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>plasma iron, ferritin, transferrin and liver enzymes)</measure>
    <time_frame>every months</time_frame>
  </secondary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Actual">15</enrollment>
  <condition>Friedreich Ataxia</condition>
  <arm_group>
    <arm_group_label>1</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Iron chelating intervention</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Iron chelating intervention</intervention_name>
    <description>Iron chelating intervention</description>
    <arm_group_label>1</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          1. Minimum age: 13 years&#xD;
&#xD;
          2. Molecular confirmation of frataxin gene mutation&#xD;
&#xD;
          3. Iron overload evaluation&#xD;
&#xD;
          4. Presence of lactate&#xD;
&#xD;
          5. Echography response to Idebenone treatment&#xD;
&#xD;
          6. Urinary test of pregnancy for girls&#xD;
&#xD;
          7. Sexual abstinence for men&#xD;
&#xD;
          8. Information consent&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          1. No disturbance of iron metabolism&#xD;
&#xD;
          2. No response to Idebenone&#xD;
&#xD;
          3. Friedreich not confirmed&#xD;
&#xD;
          4. Polynuclear neutrophils &lt;2 x 109/L or hemoglobin &lt; 8g/dL&#xD;
&#xD;
          5. No participation to other trial&#xD;
&#xD;
          6. Doubt regarding the compliance of the patient to protocol&#xD;
&#xD;
          7. Impossibility to undergo X-ray examination or presence of iron material in the&#xD;
             backbone&#xD;
&#xD;
          8. Pregnant women&#xD;
&#xD;
          9. Absence of social insurance.&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>13 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Arnold MUNNICH, Pr,MD,PhD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Assistance Publique - Hôpitaux de Paris</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Necker Hospital</name>
      <address>
        <city>Paris</city>
        <zip>75015</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>France</country>
  </location_countries>
  <verification_date>March 2007</verification_date>
  <study_first_submitted>September 16, 2005</study_first_submitted>
  <study_first_submitted_qc>September 16, 2005</study_first_submitted_qc>
  <study_first_posted type="Estimate">September 23, 2005</study_first_posted>
  <last_update_submitted>March 3, 2009</last_update_submitted>
  <last_update_submitted_qc>March 3, 2009</last_update_submitted_qc>
  <last_update_posted type="Estimate">March 4, 2009</last_update_posted>
  <responsible_party>
    <name_title>Amel Ouslimany</name_title>
    <organization>Department Clinical Research of Developpement</organization>
  </responsible_party>
  <keyword>Iron-chelating treatment</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Ataxia</mesh_term>
    <mesh_term>Cerebellar Ataxia</mesh_term>
    <mesh_term>Friedreich Ataxia</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Iron Chelating Agents</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

